On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Frank Xiaodong Gan was appointed as the senior vice president of our Company in April 2022, and is responsible for clinical development of our Group in the United States.

Dr. Gan has over 25 years of work experience in the academia and biopharmaceutical industry. Prior to joining our Company, Dr. Gan worked at Merck & Co., Inc., a multinational pharmaceutical company listed on the NYSE (stock code: MRK) as a biologist from February 2000 to September 2004 and served as a clinical research scientist from September 2004 to July 2007, during which he was responsible for clinical research and development. He served as a clinical research scientist at Bristol Myers Squibb, a multinational pharmaceutical company listed on the NYSE (stock code: BMY), from July 2007 to November 2010, during which he was responsible for early phase clinical development of antitumor drugs. Dr. Gan also served as a clinical research scientist at Eli Lilly and Company, from November 2010 to September 2016. He served as a director and a clinical project scientist of oncology at Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson which is a company listed on the NYSE (stock code: JNJ), from September 2016 to October 2018. Dr. Gan also served as the head of global clinical development at NMS Group from March 2019 to March 2022, during which he was responsible for leading the global clinical development of the company.

Dr. Gan currently serves as a member of the board of directors of Sino-American Pharmaceutical Professionals Association.

Dr. Gan obtained a bachelor’s degree in pharmacy and a master’s degree in pharmacognosy from Shanghai Medical College (currently known as Shanghai Medical College of Fudan University) in the PRC in July 1984 and October 1988, respectively. He further obtained a master’s degree in pharmaceutical sciences from North Dakota State University in the United States in December 1997. Dr. Gan obtained a doctor’s degree in pharmacy from Shenandoah University in the United States in May 2007 through attending long-distance learning courses, a non-traditional PharmD program.

Dr. Tian, Wenzhi, founder, chairman and CEO of ImmuneOnco, said:

"I am very happy and sincerely welcome Dr. Xiaodong Gan to join the ImmuneOnco team. I fully believe that he will help our company to promote the development of innovative drugs rapidly with his extensive experience in clinical trial management of anti-tumor drugs, and accelerate the realization of our great vision, "developing first-class new drugs for the benefit of tumors patients'.

"We will work with all colleagues to build the company a world-renowned biopharmaceutical company and develop first-class of new anti-cancer drugs for cancer patients all around the world."